Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1075 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: B, Growth: A, Momentum: C, Sentiment: C, Safety: B, Financials: A, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 40, which is 13 points higher than the healthcare sector average of 27. It passed 13 out of 33 due diligence checks and has average fundamentals. Bioventus has seen its stock return 39.26% over the past year, overperforming other healthcare stocks by 65 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 48.37% from Bioventus's current stock price of $10.11.

Bioventus stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Bioventus, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Amneal Pharmaceuticals (NASDAQ:AMRX) is the #2 top healthcare stock out of 1075 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Amneal Pharmaceuticals (NASDAQ:AMRX) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: C, and AI: B.

Amneal Pharmaceuticals (NASDAQ:AMRX) has a Due Diligence Score of 30, which is 3 points higher than the healthcare sector average of 27. It passed 10 out of 33 due diligence checks and has average fundamentals. Amneal Pharmaceuticals has seen its stock return 65.76% over the past year, overperforming other healthcare stocks by 91 percentage points.

Amneal Pharmaceuticals has an average 1 year price target of $17.00, an upside of 32.5% from Amneal Pharmaceuticals's current stock price of $12.83.

Amneal Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Amneal Pharmaceuticals, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Indivior Pharmaceuticals (NASDAQ:INDV) is the #3 top healthcare stock out of 1075 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Indivior Pharmaceuticals (NASDAQ:INDV) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Indivior Pharmaceuticals (NASDAQ:INDV) has a Due Diligence Score of 45, which is 18 points higher than the healthcare sector average of 27. It passed 15 out of 33 due diligence checks and has strong fundamentals. Indivior Pharmaceuticals has seen its stock return 226.06% over the past year, overperforming other healthcare stocks by 252 percentage points.

Indivior Pharmaceuticals has an average 1 year price target of $48.00, an upside of 27.46% from Indivior Pharmaceuticals's current stock price of $37.66.

Indivior Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Indivior Pharmaceuticals, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 72 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

So Young International (NASDAQ:SY) has an annual dividend yield of N/A, which is N/A percentage points lower than the healthcare sector average of 2.44%.

So Young International's dividend payout ratio of 0% indicates that its dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 22.17%, which is 20 percentage points higher than the healthcare sector average of 2.44%.

Dominari Holdings's dividend payout ratio of -42.4% indicates that its high dividend yield might not be sustainable for the long-term.

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 13.04%, which is 11 percentage points higher than the healthcare sector average of 2.44%.

Siga Technologies's dividend payout ratio of 181.8% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -0.11% in the last day, and down -0.27% over the last week. Summit Therapeutics was the among the top losers in the healthcare sector, dropping -24.91% yesterday.

Summit Therapeutics shares are trading lower. The company reported Q1 financial results.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 86, which is 71 points higher than the healthcare sector average of 15. It passed 6 out of 7 valuation due diligence checks.

Embecta's stock has dropped -24.84% in the past year. It has overperformed other stocks in the healthcare sector by 1 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 71, which is 56 points higher than the healthcare sector average of 15. It passed 5 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 386.84% in the past year. It has overperformed other stocks in the healthcare sector by 412 percentage points.

Harmony Biosciences Holdings (NASDAQ:HRMY) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 56 points higher than the healthcare sector average of 15. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 6.6% in the past year. It has overperformed other stocks in the healthcare sector by 32 percentage points.

58.7% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 40.72% over the next year.

5.34% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.17% of healthcare stocks are rated B (Buy), 49.69% are rated C (Hold), 25.34% are rated D (Sell), and 7.45% are rated F (Strong Sell).